NRAS and melanoma: Similar results were obtained with another mouse melanoma model in which the NRAS mutation is NRASG12D and the activation of the mutation occurred at 10 weeks of age in melanocytes, using the CreERt2–LoxP–tamoxifen system (Supplementary Fig. 6).